<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003440</url>
  </required_header>
  <id_info>
    <org_study_id>NN6435-4748</org_study_id>
    <secondary_id>U1111-1264-4546</secondary_id>
    <secondary_id>jRCT2071210055</secondary_id>
    <nct_id>NCT05003440</nct_id>
  </id_info>
  <brief_title>A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men</brief_title>
  <official_title>Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0385-0434 in Healthy, Male Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to look at how the study medicine works in the body and how it is&#xD;
      removed from the body.&#xD;
&#xD;
      We are testing the study medicine to make a medicine that can help people lower their&#xD;
      cholesterol level.&#xD;
&#xD;
      Participants will either get&#xD;
&#xD;
        1. NNC0385-0434 (a potential new medicine) in one of three different doses: 15 mg, 40 mg,&#xD;
           or 100 mg.&#xD;
&#xD;
        2. placebo (a dummy medicine which looks like the study medicine but without any medicine).&#xD;
&#xD;
      Which treatment participants get is decided by chance. NNC0385-0434 is a new medicine and has&#xD;
      not been approved by the Health Authorities (Centre for Drug Evaluation).&#xD;
&#xD;
      Participants will get 1 tablet per day for 10 days. The tablet will be handed out by a study&#xD;
      doctor or site staff at the clinic and the study will last between 62 and 98 days.&#xD;
&#xD;
      Participants will have 7 clinic visits. One of these visits will be a 13-day, 12-night stay&#xD;
      (V2) and the rest will be 1-day visits (V1 and V3 to V7).&#xD;
&#xD;
      At all visits, except the information visit, participants will have blood drawn along with&#xD;
      other clinical checks.&#xD;
&#xD;
      Participants will be asked about their health, medical history and habits including mental&#xD;
      health.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">February 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 11, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study consists of two parts. Part 1 consists of three sequential dose ascension cohorts each with 4 healthy Japanese participants, randomised 3:1. The purpose of Part 1 is to provide safety clearance for initiating Part 2 and the randomisation of Japanese participants into the phase 2 study NN6435-4697. Part 2 will randomise the remaining Japanese participants into three parallel dose groups. (3:1:3:1:3:1).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From pre-dose (day 1) until completion of the post-treatment period at follow-up (day 65)</time_frame>
    <description>Count of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-24h,0434,Day10,; the area under the NNC0385-0434 plasma concentration-time curve from time 0 to 24 h after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) 0 to 24 hours post treatment (day 11)</time_frame>
    <description>h*nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,0434,Day10,; the maximum plasma concentration of NNC0385-0434 after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) 0 hours to post treatment follow-up (day 65)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,0434,Day10; the time to maximum observed plasma concentration of NNC0385-0434 after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) 0 hours to post treatment follow-up (day 65)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½,0434,Day10; the terminal half-life of NNC0385-0434 after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) 0 hours to post treatment follow-up (day 65)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24h,SNAC,Day10,; the area under the SNAC plasma concentration-time curve from time 0 to 24 h after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) 0 to 24 hours post treatment (day 11)</time_frame>
    <description>h*nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,SNAC,Day10; the maximum plasma concentration of SNAC after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) 0 to 24 hours post treatment (day 11)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,SNAC,Day10; the time to maximum observed plasma concentration of SNAC after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) 0 to 24 hours post treatment follow-up (day 11)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½,SNAC,Day10; the terminal half-life of SNAC after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) 0 to 24 hours post treatment follow-up (day 11)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>NNC0385-0434 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NNC0385-0434 15 mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo will be administered once-daily over 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0385-0434 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NNC0385-0434 40 mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo will be administered once-daily over 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0385-0434 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NNC0385-0434 100 mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo will be administered once-daily over 10 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0385-0434</intervention_name>
    <description>Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg</description>
    <arm_group_label>NNC0385-0434 100 mg</arm_group_label>
    <arm_group_label>NNC0385-0434 15 mg</arm_group_label>
    <arm_group_label>NNC0385-0434 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will get 1 tablet (oral use) of placebo per day for 10 days</description>
    <arm_group_label>Placebo (NNC0385-0434 100 mg)</arm_group_label>
    <arm_group_label>Placebo (NNC0385-0434 15 mg)</arm_group_label>
    <arm_group_label>Placebo (NNC0385-0434 40 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight greater than or equal to 54.0 kg.&#xD;
&#xD;
          -  Body mass index (BMI) between 20.0 and 34.9 kg/m^2 (both inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of clinically significant gastrointestinal disorders potentially affecting&#xD;
             absorption of drugs and/or nutrients, as judged by the investigator.&#xD;
&#xD;
          -  Any disorder, which in the investigator's opinion might jeopardise participant's&#xD;
             safety or compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>&quot;According to the Novo Nordisk disclosure commitment on novonordisk-trials.com&quot;</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

